AGENDIA®

May 2021

Key Investment Highlights

1. Pioneer in Breast Cancer Capturing Entire Patient Lifecycle
2. Scaled, Commercial-stage Business Growing 30% Annually
3. Foundational Strength in Early Interception of Treatment Decisions
4. Breakout Growth Driven by Liquid Biopsy and AI-Enabled Solutions
5. Extensive Clinical Trial Validation and Continuous Evidence Generation
6. Clear Pathway to the $12B Global Market Opportunity

Agendia Overview

Business Description

- Agendia is the only molecular diagnostics company focused on the entire breast cancer continuum of care
  - Targets a global market opportunity of ~$12bn across the full patient lifecycle
  - Over 150,000 patients worldwide with 235 million covered lives in the US
- Scaled, commercial-stage genomic testing platform generating patient-specific, clinically actionable data about the unique biology of a woman's breast cancer
  - Provides rapid and precise analysis enabling multidisciplinary care teams to better counsel patients on the best possible treatment options for their breast cancer
  - Allows for highly effective treatment approaches that improve patient outcomes and quality of life while saving the healthcare system from unnecessary costs
  - Backed by prestigious physicians and institutions globally, shifting the standard of care towards more ideal, personalized treatment
- 2020 revenue of $58mm[1] demonstrating strong revenue growth vs. prior year revenue of $50mm reflecting deeper market penetration fueled by established and expanding payor reimbursement.

Key Highlights

$58M[1]
2020 Revenue

+30%
CAGR 2021 - 2024

~74%
Gross Margin

- +25,000 Cases in 2020
- 30 Clinical Studies with 30K+ Women Globally
- +150 Publications
- +235M U.S. Covered Lives
- Multiple Clearances 510(k), CE
- Marquee Partnerships: PAIGE.AI, Inivata

Agendia's Solutions Address the Entire Breast Cancer Continuum of Care

EARLY — RISK SCORING / TREATMENT SECTION

Diagnosis → Treatment

AGENDIA MAMMAPRINT · AGENDIA BLUEPRINT · Paige

MammaPrint & BluePrint
Risk Scoring | Subtyping

MID — MONITORING

Treatment → Remission or Cure

Inivata

RaDaR MRD Test
Liquid Biopsy Monitoring

LATE — METASTATIC PROFILING

Remission or Cure → Recurrence

Smart Pathology
Metastatic Profiling

AGENDIA

1 – unaudited revenue for the year ended December 31, 2020.

Agendia is Driving Early Interception of Treatment Decisions

Trend Towards Pre-Operative Treatment Enabled by MammaPrint and BluePrint

Day	0	1-2	2-3	4-5	7	10-14
Breast Cancer Treatment Process	Presentation Biopsy	Diagnosis ER/PR/HER2 Ordered	ER/PR/HER2 Available	Pre-Operative Treatment Plan	 Surgery	Post-Operative Treatment Determined

Traditional Timeline

FFPE block ordered and sent → Results Available Day 12+

AGENDIA

FFPE block ordered and sent → Results Available Day 3-4 → Optimal pathway identified → Patient treatment

Agendia can uniquely help guide Neoadjuvant treatment vs. surgery decision

MINDACT Trial Prospectively Validated MammaPrint

Clinically high risk patients **reclassified as genomically low risk** by MammaPrint



of clinically high-risk patients reclassified.
As low risk, these women were
SPARED ADJUVANT CHEMOTHERAPY



of patients who **did not receive chemotherapy and were FREE OF DISTANT METASTASIS* AT 5 YEARS**

Clinicians identify patients who would not benefit and can be spared from toxic chemotherapy

Clinical Trial & Evidence Generation Engines

The I-SPY Trials

Unique Trial & Drug Access

All patients screened exclusively with MP & BP

- 20+ Pharma & Biotech Partnerships
- Adaptive trial with 2k+ high risk patients
- Engine for clinical trials and novel signatures

FLEX Registry

Proprietary Data

Clinical registries driving sticky business (and data)

- 90 US sites (10 NCCNs) incl. US Oncology
- 7k registry patients today, 30k by YE2026
- Genome data linked to real-world outcomes

Capturing the Patient Lifecycle: $12B TAM



	EARLY	MID	LATE
PATIENTS	750,000	4 million	700,000
PRICE & FREQUENCY	**$3,000** One-time within 5 years of diagnosis	**$1,500** One-time **$300** Annually	**$4,000** Every 2-3 years
TAM	**$2.2B**	**$7.0B**	**$2.8B**

+$10,000 of Patient "Lifetime Value"

Source: American Cancer Society; World Health Organization; World Cancer Research Foundation; BCC Research; Analyst Estimates

Multiple Levers for Breakout Growth

Significant growth driven by further core market penetration, enhanced digital capabilities and expansion across the continuum of breast cancer care



Core Platform Expansion

- Expanding platform to cover all breast cancer subtypes
- Extending diagnostic window – Five years after initial diagnosis
- Addressing new patient cohorts, including young women and diverse ethnicities
- New signatures – Rx response, novel Rx

Expanding Continuum of Care

- Earlier interception through Neoadjuvant Rx guidance
- Serial monitoring of residual disease through liquid biopsy
- Capturing later stage patients through metastatic profiling

Global Health & Health Data

- Offering decentralized, global solutions – NGS kits, CloudLab
- Utilizing AI to deliver comprehensive and data-driven treatment and diagnosis insights globally
- Expanding proprietary data registry (FLEX)

Recent Marquee Partnerships Driving Future Growth

AI Pathology: Paige

Integrated Genomic Information and AI Pathology

AGENDIA *powered by* Paige

- **Global leader in AI-driven pathology and digital diagnostics**
  - Spin-out of Memorial Sloan Kettering
- **Co-developing digital tests and integrated breast cancer treatment planning tools**
  - Cloud-based Paige Platform with genomic information from Agendia's proprietary MammaPrint® and BluePrint® tests
- **Key Benefits**
  - Faster access to predictive and prognostic information along the entire continuum of care
  - Same-day turnaround enabling earlier intervention
  - Preserve limited biopsy or surgical tissue specimens
  - Extend access to testing to physicians and their patients through 'digital diagnostics'

Liquid Biopsy: Inivata

Critical Capabilities to Effectively Monitor Response and Recurrence

AGENDIA *powered by* Inivata

- **Emerging leader in liquid biopsy**
  - RaDaR® is a highly sensitive liquid biopsy assay that tracks up to 48 tumor-specific variants allowing for the detection of Minimal Residual Disease and early detection of relapse
- **Agendia gains co-exclusive rights to distribute RaDaR® in North America and Europe**
  - Provides a natural progression in guiding breast cancer care from diagnosis to surgery and treatment to monitoring
- **Key Benefits**
  - Enables better triage in pre- and post-operative care
  - Improves monitoring early indicators of relapse
  - Expands Agendia's addressable markets with a repeat testing model
  - Provides a comprehensive offering across the continuum